[go: up one dir, main page]

EA201270099A1 - Транс-4-[[(5s)-5-[[[3,5-бис(трифторметил)фенил]метил](2-метил-2h-тетразол-5-ил)амино]-2,3,4,5-тетрагидро-7,9-диметил-1h-1-бензазепин-1-ил]метил]циклогексанкарбоновая кислота - Google Patents

Транс-4-[[(5s)-5-[[[3,5-бис(трифторметил)фенил]метил](2-метил-2h-тетразол-5-ил)амино]-2,3,4,5-тетрагидро-7,9-диметил-1h-1-бензазепин-1-ил]метил]циклогексанкарбоновая кислота

Info

Publication number
EA201270099A1
EA201270099A1 EA201270099A EA201270099A EA201270099A1 EA 201270099 A1 EA201270099 A1 EA 201270099A1 EA 201270099 A EA201270099 A EA 201270099A EA 201270099 A EA201270099 A EA 201270099A EA 201270099 A1 EA201270099 A1 EA 201270099A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methyl
benzazepin
tetrazol
tetrahydro
bis
Prior art date
Application number
EA201270099A
Other languages
English (en)
Other versions
EA020600B1 (ru
Inventor
Синьчао Чэнь
Скотт Алан Фрэнк
Дэвид Майкл Ремик
Стивен Уэйн Педерсен
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42352717&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201270099(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201270099A1 publication Critical patent/EA201270099A1/ru
Publication of EA020600B1 publication Critical patent/EA020600B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Предложены соединения формулыназванные транс-4-[[(5S)-5-[[[3,5-бис(трифторметил)фенил]метил](2-метил-2Н-тетразол-5-ил)амино]-2,3,4,5-тетрагидро-7,9-диметил-1Н-1-бензазепин-1-ил]метил]циклогексанкарбоновой кислотой, в виде их свободной кислоты или фармацевтически приемлемой соли, гидрата и гидрата в кристаллической форме; фармацевтические составы и способы их применения.
EA201270099A 2009-06-30 2010-06-28 Транс-4-[[(5s)-5-[[[3,5-бис-(трифторметил)фенил]метил](2-метил-2h-тетразол-5-ил)амино]-2,3,4,5-тетрагидро-7,9-диметил-1н-1-бензазепин-1-ил]метил]циклогексанкарбоновая кислота EA020600B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22170809P 2009-06-30 2009-06-30
PCT/US2010/040125 WO2011002696A1 (en) 2009-06-30 2010-06-28 Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid

Publications (2)

Publication Number Publication Date
EA201270099A1 true EA201270099A1 (ru) 2012-05-30
EA020600B1 EA020600B1 (ru) 2014-12-30

Family

ID=42352717

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201270099A EA020600B1 (ru) 2009-06-30 2010-06-28 Транс-4-[[(5s)-5-[[[3,5-бис-(трифторметил)фенил]метил](2-метил-2h-тетразол-5-ил)амино]-2,3,4,5-тетрагидро-7,9-диметил-1н-1-бензазепин-1-ил]метил]циклогексанкарбоновая кислота

Country Status (37)

Country Link
US (2) US8329688B2 (ru)
EP (1) EP2448933B1 (ru)
JP (1) JP5689875B2 (ru)
KR (1) KR101404893B1 (ru)
CN (1) CN102639528B (ru)
AR (1) AR077208A1 (ru)
AU (1) AU2010266537B2 (ru)
BR (1) BRPI1011931A2 (ru)
CA (1) CA2764425C (ru)
CL (1) CL2011003263A1 (ru)
CO (1) CO6480934A2 (ru)
CR (1) CR20110669A (ru)
DK (1) DK2448933T3 (ru)
DO (1) DOP2011000405A (ru)
EA (1) EA020600B1 (ru)
EC (1) ECSP11011551A (ru)
ES (1) ES2435293T3 (ru)
GT (1) GT201100321A (ru)
HR (1) HRP20130950T1 (ru)
IL (1) IL216655A (ru)
JO (1) JO2867B1 (ru)
MA (1) MA33385B1 (ru)
ME (1) ME01606B (ru)
MX (1) MX2011014024A (ru)
MY (1) MY157121A (ru)
NZ (1) NZ596820A (ru)
PE (1) PE20120538A1 (ru)
PL (1) PL2448933T3 (ru)
PT (1) PT2448933E (ru)
RS (1) RS52988B (ru)
SG (1) SG177413A1 (ru)
SI (1) SI2448933T1 (ru)
TN (1) TN2011000638A1 (ru)
TW (1) TWI450896B (ru)
UA (1) UA109409C2 (ru)
WO (1) WO2011002696A1 (ru)
ZA (1) ZA201108707B (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1761521A1 (en) * 2004-06-24 2007-03-14 Eli Lilly And Company Compounds and methods for treating dyslipidemia
TWI450896B (zh) * 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
KR20190025737A (ko) 2011-07-08 2019-03-11 노파르티스 아게 높은 트리글리세리드 대상체에서의 아테롬성동맥경화증의 치료 방법
WO2014012401A1 (zh) * 2012-07-16 2014-01-23 上海恒瑞医药有限公司 苯并七元杂环类衍生物、其制备方法及其在医药上的应用
HUE033790T2 (en) 2013-01-31 2017-12-28 Chong Kun Dang Pharmaceutical Corp Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as cetp inhibitors
CN105017085B (zh) * 2014-04-28 2018-06-29 中国科学院上海药物研究所 一类kcnq钾通道激动剂、其制备方法和用途
CA2953483C (en) 2014-07-30 2023-04-04 F. Hoffmann-La Roche Ag Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent
TWI691331B (zh) 2014-09-26 2020-04-21 日商興和股份有限公司 脂質異常症治療劑
CN108456213B (zh) * 2017-02-22 2021-01-15 浙江九洲药业股份有限公司 一种3-氟-4-羟基环己烷羧酸酯的制备方法
WO2025093129A1 (en) 2023-11-01 2025-05-08 Newamsterdam Pharma B.V. Treatment and prevention of age-related macular degeneration using a cetp inhibitor

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4948639B1 (ru) 1970-12-15 1974-12-23
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
HN2000000203A (es) 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
CO5271716A1 (es) 1999-11-30 2003-04-30 Pfizer Prod Inc Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
MXPA03009935A (es) 2001-04-30 2004-01-29 Pfizer Prod Inc Metodos e intermedios para preparar inhibidores 4-aminoquinolina de cetp.
TR200401413T1 (tr) 2002-08-30 2005-06-21 Japan Tobacco Inc. Dibenzilamin bileşikleri ve bunların farmasötik kullanımları
MXPA05003456A (es) 2002-10-04 2005-07-05 Millennium Pharm Inc Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias.
WO2004078730A2 (en) 2003-03-04 2004-09-16 Takasago International Corporation Method for producing optically active amines
US20040204450A1 (en) 2003-03-28 2004-10-14 Pfizer Inc Quinoline and quinoxaline compounds
KR20060085675A (ko) 2003-10-08 2006-07-27 일라이 릴리 앤드 캄파니 이상지혈증 치료를 위한 화합물 및 방법
JP2007530550A (ja) 2004-03-26 2007-11-01 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物および方法
EP1761521A1 (en) * 2004-06-24 2007-03-14 Eli Lilly And Company Compounds and methods for treating dyslipidemia
CN1972927A (zh) * 2004-06-24 2007-05-30 伊莱利利公司 用于治疗血脂障碍的化合物和方法
US7700774B2 (en) 2004-12-20 2010-04-20 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds and their pharmaceutical compositions
TWI450896B (zh) * 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸

Also Published As

Publication number Publication date
CR20110669A (es) 2012-03-16
NZ596820A (en) 2013-07-26
SI2448933T1 (sl) 2013-11-29
KR20120027426A (ko) 2012-03-21
TW201113275A (en) 2011-04-16
IL216655A0 (en) 2012-02-29
US8329688B2 (en) 2012-12-11
PT2448933E (pt) 2013-10-29
AU2010266537A1 (en) 2012-02-02
IL216655A (en) 2015-02-26
JP2012532106A (ja) 2012-12-13
TN2011000638A1 (en) 2013-05-24
HRP20130950T1 (hr) 2013-11-22
MY157121A (en) 2016-05-13
ECSP11011551A (es) 2012-01-31
SG177413A1 (en) 2012-02-28
JP5689875B2 (ja) 2015-03-25
CL2011003263A1 (es) 2012-07-27
DOP2011000405A (es) 2012-01-15
DK2448933T3 (da) 2013-10-07
JO2867B1 (en) 2015-03-15
PL2448933T3 (pl) 2014-01-31
CO6480934A2 (es) 2012-07-16
MA33385B1 (fr) 2012-06-01
ES2435293T3 (es) 2013-12-18
CN102639528B (zh) 2014-07-16
CA2764425C (en) 2015-01-06
US20100331309A1 (en) 2010-12-30
EA020600B1 (ru) 2014-12-30
CA2764425A1 (en) 2011-01-06
TWI450896B (zh) 2014-09-01
US8299060B2 (en) 2012-10-30
BRPI1011931A2 (pt) 2016-04-19
EP2448933A1 (en) 2012-05-09
CN102639528A (zh) 2012-08-15
WO2011002696A1 (en) 2011-01-06
US20120058990A1 (en) 2012-03-08
GT201100321A (es) 2012-11-15
PE20120538A1 (es) 2012-05-09
EP2448933B1 (en) 2013-08-28
KR101404893B1 (ko) 2014-06-20
UA109409C2 (ru) 2015-08-25
AU2010266537B2 (en) 2013-04-18
MX2011014024A (es) 2012-04-20
ME01606B (me) 2014-09-20
RS52988B (en) 2014-02-28
ZA201108707B (en) 2013-05-29
AR077208A1 (es) 2011-08-10

Similar Documents

Publication Publication Date Title
EA201270099A1 (ru) Транс-4-[[(5s)-5-[[[3,5-бис(трифторметил)фенил]метил](2-метил-2h-тетразол-5-ил)амино]-2,3,4,5-тетрагидро-7,9-диметил-1h-1-бензазепин-1-ил]метил]циклогексанкарбоновая кислота
WO2012007869A3 (en) N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
EA201001368A1 (ru) Гетероциклические производные мочевины и способы их применения-211
EA201070164A1 (ru) Твердый препарат, включающий алоглиптин и гидрохлорид метформина
SMT201300098B (it) Forme solide di N-(4-(7-azabiciclo[2.2.1]eptan-7-il)-2-(trifluorometil)fenil-4-osso-5-trifluorometil)-1,4-diidrochinolina-3-carbossammide
WO2009016460A3 (en) Pyrazole compounds and their use as raf inhibitors
NZ594641A (en) Pyrazole derivatives used as ccr4 receptor antagonists
EA201101301A1 (ru) Натриевая соль 5-циклопропил-2-{[2-(2,6-дифторфенил)пиримидин-5-ил]амино}бензойной кислоты в качестве ингибиторов dhodh
TW200745097A (en) 4-Phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carboxylic acid amides as PLK1 inhibitors
JP2012512863A5 (ru)
NZ598918A (en) Nitrogen-containing compounds and pharmaceutical compositions thereof for the treatment of atrial fibrillation
MEP33308A (en) Benzimidazole derivative and use as angiotensin ii antagonist
EA201001858A1 (ru) Гетероциклические производные мочевины для лечения бактериальных инфекций
EA201001859A1 (ru) Гетероциклические производные мочевины и способы их применеия
EA201270266A1 (ru) Гетероциклические соединения
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
MX2010012421A (es) 5-[5-[2-(3,5-bis(trifluormetil)fenil)-2-metilpropanoilmetilamino] -4-(4-fluoro-2-metilfenil)]-2-piridinil-2-alquil-prolinamida como antagosnistas del receptor de neurocinina 1.
WO2006051314A8 (en) Guanidine derivatives as inhibitors of ddah
DE602004031878D1 (de) Immunhemmende pyrazolon-verbindungen
RS54001B1 (en) SUBSTITUTED [(5H-Pyrrolo [2,1-C] [1,4] BENZODIAZEPIN-11-IL-) PIPERAZIN-1-IL] -2,2-DIMETHYLPROPANOIC ACID COMPOUNDS HT 2A
CY1114514T1 (el) Τrανs-4-[[(5s)-5-[[[3,5-δις(τριφθορομεθυλ)φαινυλ]μεθυλ](2-μεθυλ-2η-τετραζολ-5-υλ)αμινο]-2,3,4,5-τετραϋδρο-7,9-διμεθυλ-1η-1-βενζαζεπιν-1 -υλ]μεθυλ]-κυκλοεξανο-καρβοξυλικο οξυ
AR083322A1 (es) Compuesto (3-{[{4-[4-amino-2-(etoximetil)-1h-imidazol[4,5-c]quinolin-1-il]butil}(n,n-dietilglicil)amino]metil}fenil)acetato de metilo
EA200970496A1 (ru) Соединения 2-алкилиндазола для лечения некоторых расстройств цнс
TH125824A (th) 2-อะมิโน-5,5-ไดฟลูออโร-5,6-ไดไฮโดร-4H-ออกซาซิน ซึ่งเป็นสารยับยั้ง Bace 1 และ/หรือ Bace 2

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ BY KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM KZ RU